This event is currently fully booked. If you’d like to be added to the cancellation list, please call us on 9667 8181.
Clinical trials are a vital strategy for ensuring better health and patient access to cutting-edge therapies. They are also the essential pathway to the development of new medical products, to translate research findings into clinical outcomes and secure economic growth opportunities for Victoria.
This event will explore Victoria’s strengths in clinical trials, discuss changes in the global clinical trials landscape and identify opportunities to strengthen Victoria as a leading clinical trials destination.
The event will also include the official launch of the Victorian Clinical Trials Portal by the Hon. Minister Philip Dalidakis.
The Victorian Clinical Trials Gateway (VCT Gateway) – a web-based portal – has been launched to globally connect the clinical trials ecosystem with and in Victoria.
The VCT Gateway promotes clinical trials in Victoria and positions Victoria as the portal of entry into conducting clinical trials in Australia – providing a cohesive, holistic, single-stop solution for companies from start-ups, to major pharmaceutical companies, clinical research organisations who want to conduct high-quality clinical trials, quickly and cost-effectively.
Following the launch, the format will include short speaker presentations followed by a facilitated Q&A session with a panel of speakers.
Date: Tuesday 6th March 2018
Time: Registration from 7:20 am for a 7.30 am breakfast networking followed by presentations and discussion from 8.00am – 9:00 am
Venue: The Education Centre, Level 3-Healy Wing, St Vincent’s Hospital Melbourne, 41 Victoria Pde, Fitzroy
BioMelbourne Network Members: $65 (incl. GST)
Non Members: $130 (incl. GST)
To check if your organisation is a member, click here
A full refund is given up to 7 days prior to the event
No refunds within 7 days of the event
Confirmed Speakers & Panellists:
Tina leads the company strategy and operations for academic and commercial sponsors. Prior to her role with Neuroscience Trials Australia, Tina was the director of clinical development at Acrux Pharma Pty Ltd, a successful Australian biotechnology company. She managed the strategic direction, development, co-ordination and reporting of the company’s clinical programs. Tina is an experienced driver of clinical drug development, particularly in the design, management and implementation of clinical trials and has worked as a clinical researcher and in senior roles within the pharmaceutical and biotechnology industry for over 25 years. Her experience encompasses all stages of drug development in many therapeutic areas and geographical regions.
Ben Laverty, Director – Site Management, IQVIA
Ben has 18 years’ experience working in Australia and the UK across R&D and Clinical Trial Management in both Pharma and CRO. As Director of Site Management at IQVIA Ben is responsible for the oversight and delivery of site monitoring activities across ~150 active clinical trials in Australia and New Zealand.
Carrie Bloomfield, Associate Director and Head of Clinical Research, GlaxoSmithKline Australia
Carrie joined GSK Australia in February 2016 and has over 20 years’ experience in the clinical trials environment in both Clinical Research Organisation and Pharmaceutical companies. Prior to GSK, Carrie held various roles at IQVia (formerly, Quintiles) over 11 years with her last role being Head of Clinical Project Management, Australia and New Zealand. Throughout her career Carrie has held roles in Clinical Research, Clinical QA, Central Laboratory management and Project Management. More recently Carrie joined the Medicines Australia/Medical Technology Association of Australia R & D Taskforce where she holds co-chair responsibilities.
Prof. Alex Thompson, Professor-Director of the Department of Gastroenterology at St Vincent’s Hospital and the University of Melbourne, Australia, NHMRC Practitioner Fellow and Adjunct Assistant Professor of the Department of Gastroenterology, Duke University Medical Center.
Alex Thompson is Professor-Director of the Department of Gastroenterology at St Vincent’s Hospital and the University of Melbourne, Australia, NHMRC Practitioner Fellow and Adjunct Assistant Professor of the Department of Gastroenterology, Duke University Medical Center. Professor Thompson is the Program Director for the Victorian Statewide Hepatitis Service, Australia, contracted to the Victorian Government’s Department of Justice and Regulation, and the current President of the Australian Liver Association. His research focusses on improving outcomes for people living with viral hepatitis. He was involved in the discovery of IL28B polymorphism as a predictor of treatment outcome in HCV, and is an active clinical investigator for trials evaluating the efficacy of novel antiviral DAA regimens. With the development of DAA therapy for HCV, he has more recently been actively pursuing the development and evaluation of new models of care for people with HCV, with a focus on prisoners and treatment as prevention to eliminate transmission and reduce prevalence of HCV in Australia. He has published widely in journals including Nature, New England Journal of Medicine, Journal of the American Medical Association, Gastroenterology, Hepatology, Gut and Journal of Hepatology.